Alkermes to Report Third Quarter Financial Results on October 25, 2023

Rhea-AI Summary

Alkermes to discuss Q3 financial results and clinical data on ALKS 2680 in conference call and webcast

Positive

• Alkermes to present initial clinical data on ALKS 2680 for narcolepsy treatment

Negative

• None.

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023 to discuss the company's third quarter financial results as well as initial clinical data related to ALKS 2680, the company's novel, investigational orexin 2 receptor agonist in development for the treatment of narcolepsy, that will be presented at World Sleep Congress.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-25-2023-301960854.html

SOURCE Alkermes plc

FAQ

When will Alkermes host the conference call and webcast?

Alkermes will host the conference call and webcast on Wednesday, Oct. 25, 2023.

What will be discussed in the conference call and webcast?

The company's third quarter financial results and initial clinical data on ALKS 2680 will be discussed.

What is ALKS 2680?

ALKS 2680 is Alkermes' novel, investigational orexin 2 receptor agonist in development for the treatment of narcolepsy.

Where can I access the webcast?

The webcast can be accessed on the Investors section of Alkermes' website at www.alkermes.com.

How can I join the conference call?

U.S. callers can dial +1 877 407 2988, and international callers can dial +1 201 389 0923.

Will there be a replay of the webcast?

Yes, a replay of the webcast will be available on Alkermes' website approximately two hours after the event.